gefitinib has been researched along with shikonin in 5 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (shikonin) | Trials (shikonin) | Recent Studies (post-2010) (shikonin) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 660 | 2 | 505 |
| Protein | Taxonomy | gefitinib (IC50) | shikonin (IC50) |
|---|---|---|---|
| Epidermal growth factor receptor | Homo sapiens (human) | 0.1392 | |
| DNA topoisomerase 2-alpha | Homo sapiens (human) | 6.6 | |
| Pyruvate kinase PKM | Homo sapiens (human) | 6.2933 | |
| M-phase inducer phosphatase 1 | Homo sapiens (human) | 0.22 | |
| M-phase inducer phosphatase 2 | Homo sapiens (human) | 0.4 | |
| DNA topoisomerase 2-beta | Homo sapiens (human) | 6.6 | |
| Class A sortase SrtA | Staphylococcus aureus | 2.65 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, X; Han, H; Han, M; He, C; Hu, J; Lin, F; Lin, H; Luo, Y; Qi, J; Wen, Z; Yang, M; Yang, R; Yang, Y; Yin, T | 1 |
| Chow, LW; Fan, XX; Jiang, ZB; Leung, EL; Li, X; Liu, L; Loo, WT; Yao, XJ | 1 |
| Chen, JY; Jiang, Z; Long, F; Ren, YG; Tang, JC; Zhao, J | 1 |
| Ding, K; Hu, X; Li, QY; Li, YL; Lin, NM; Tan, BQ; Wang, F; Zhang, B; Zhang, C | 1 |
| Chen, H; Chen, Q; Han, H; Lin, H; Lu, G; Ma, Y; Qi, J; Wang, C; Wang, X; Wen, Z; Yang, M; Yang, Y; Yin, T | 1 |
5 other study(ies) available for gefitinib and shikonin
| Article | Year |
|---|---|
Shikonin N-benzyl matrinic acid ester derivatives as novel telomerase inhibitors with potent activity against lung cancer cell lines.
Topics: Alkaloids; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Enzyme Inhibitors; G2 Phase Cell Cycle Checkpoints; Humans; Lung Neoplasms; Matrines; Molecular Docking Simulation; Naphthoquinones; Protein Binding; Quinolizines; Telomerase | 2022 |
Shikonin inhibits gefitinib-resistant non-small cell lung cancer by inhibiting TrxR and activating the EGFR proteasomal degradation pathway.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; High-Throughput Screening Assays; Humans; Lung Neoplasms; Mutation; Naphthoquinones; Neoplasm Recurrence, Local; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Thioredoxin-Disulfide Reductase | 2017 |
Shikonin enhances sensitization of gefitinib against wild-type EGFR non-small cell lung cancer via inhibition PKM2/stat3/cyclinD1 signal pathway.
Topics: A549 Cells; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Carrier Proteins; Cell Line, Tumor; Cell Survival; Cyclin D1; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Membrane Proteins; Mice; Mice, Nude; Naphthoquinones; Quinazolines; Signal Transduction; Sincalide; STAT3 Transcription Factor; Thyroid Hormone-Binding Proteins; Thyroid Hormones | 2018 |
Shikonin sensitizes wild‑type EGFR NSCLC cells to erlotinib and gefitinib therapy.
Topics: A549 Cells; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lithospermum; Lung Neoplasms; Mice, Nude; Naphthoquinones; Protein Kinase Inhibitors; Reactive Oxygen Species | 2018 |
PKM2/PDK1 dual-targeted shikonin derivatives restore the sensitivity of EGFR-mutated NSCLC cells to gefitinib by remodeling glucose metabolism.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Gefitinib; Glucose; Lung Neoplasms; Mice; Oxidoreductases; Pyruvate Kinase | 2023 |